Serum Prolidase Enzyme Activity Level: Not a Predictive Biomarker for Epilepsy
| Autor: | Mehmet Akdogan, Zeynep Özözen Ayas, Mustafa Ercan Gunel, Dilcan Kotan |
|---|---|
| Přispěvatelé: | Ayas, ZO, Kotan, D, Akdogan, M, Gunel, ME, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Kotan Dündar, Dilcan, Akdoğan, Mehmet, Günel, Mustafa Ercan |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Inflammation medicine.disease_cause Gastroenterology Pathogenesis 03 medical and health sciences Epilepsy 0302 clinical medicine Internal medicine General & Internal Medicine medicine Proline Predictive biomarker lcsh:R5-920 biology business.industry food and beverages General Medicine medicine.disease Enzyme assay 030104 developmental biology biology.protein Biomarker (medicine) Original Article medicine.symptom business lcsh:Medicine (General) 030217 neurology & neurosurgery Oxidative stress |
| Zdroj: | Eurasian Journal of Medicine, Vol 51, Iss 1, Pp 27-30 (2019) |
| Popis: | Objective Oxidative stress (OS) and inflammation are considered responsible for the pathogenesis of epilepsy. Prolidase has an extremely important role in proline recycling for collagen synthesis. Higher than normal proline levels have been shown to increase OS. Furthermore, prolidase activity is associated with inflammation during fibrotic process. No study has yet investigated the relationship between epilepsy and prolidase enzyme activity (PEA). In this study, we aimed to contribute to the existing literature by assessing postictal PEA levels, which are correlated with inflammation and OS, to determine whether PEA levels may be used as a biomarker for epilepsy. Materials and methods This study included patients with epilepsy who presented to the emergency department within first 6 h of a seizure. Results The epileptic group included 27 patients (16 males, 11 females) and the control group included 31 healthy individuals (11 males, 20 females). The mean age of the epilepsy (n=27) and healthy control group (n=31) was 43.1±20.2 and 51.9±21 years, respectively. Serum PEA levels were 1171.90±343.3 in the epileptic group and 1137.1±295.6 in the control group. There were no significant differences between two groups (p>0.05). Conclusion Our study results suggest that although PEA is an enzyme associated with OS and inflammation, it is still not an ideal biomarker for epileptic patients. This study is important because it investigated PEA in patients with idiopathic epilepsy for the first time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|